Simon Mcnamara

Stevenage, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Journal: The Lancet. Haematology

Published: May 23, 2025

Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.

Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.

Journal: Future oncology (London, England)

Published: May 12, 2025

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis.

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis.

Journal: American journal of hematology

Published: February 28, 2025

Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey.

Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey.

Journal: Future oncology (London, England)

Published: February 04, 2025

Corrigendum to 'Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment' [Soc. Sci. Med. Volume 269, January 2021, 113573].

Corrigendum to 'Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment' [Soc. Sci. Med. Volume 269, January 2021, 113573].

Journal: Social science & medicine (1982)

Published: February 02, 2025

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Journal: The Lancet. Haematology

Published: January 16, 2025

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.

Journal: Frontiers in oncology

Published: December 23, 2024

Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.

Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.

Journal: PloS one

Published: August 07, 2024

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

Journal: The New England journal of medicine

Published: June 03, 2024

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

Journal: British journal of haematology

Published: April 23, 2024

Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions.

Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions.

Journal: PharmacoEconomics

Published: March 06, 2023

Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis.

Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality Into Cost-Effectiveness Analysis.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: December 01, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026